Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
Public ClinicalTrials.gov record NCT03077841. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Study identification
- NCT ID
- NCT03077841
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 928 participants
Conditions and interventions
Conditions
- Ductal Breast Carcinoma In Situ
- Early-Stage Breast Carcinoma
- Invasive Breast Carcinoma
- Stage 0 Breast Cancer AJCC v6 and v7
- Stage I Breast Cancer AJCC v7
- Stage IA Breast Cancer AJCC v7
- Stage IB Breast Cancer AJCC v7
- Stage II Breast Cancer AJCC v6 and v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
Interventions
- Laboratory Biomarker Analysis Other
- Partial Breast Irradiation Radiation
- Questionnaire Administration Other
Other · Radiation
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2017
- Primary completion
- Nov 7, 2027
- Completion
- Nov 7, 2027
- Last update posted
- Mar 4, 2026
2017 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| Piedmont Hospital | Atlanta | Georgia | 30309 | — |
| Community Cancer Center East | Indianapolis | Indiana | 46219 | — |
| Covenant Medical Center Harrison | Saginaw | Michigan | 48602 | — |
| Summit Medical Group | Berkeley Heights | New Jersey | 07922 | — |
| Cooper Hospital University Medical Center | Camden | New Jersey | 08103 | — |
| MD Anderson Cancer Center at Cooper-Voorhees | Voorhees Township | New Jersey | 08043 | — |
| Presbyterian Hospital | Albuquerque | New Mexico | 87106 | — |
| OhioHealth Mansfield Hospital | Mansfield | Ohio | 44903 | — |
| MD Anderson in The Woodlands | Conroe | Texas | 77384 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| MD Anderson West Houston | Houston | Texas | 77079 | — |
| MD Anderson League City | League City | Texas | 77573 | — |
| Saint Luke's Baptist Health System | San Antonio | Texas | 78229 | — |
| MD Anderson in Sugar Land | Sugar Land | Texas | 77478 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03077841, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03077841 live on ClinicalTrials.gov.